Derek Finnegan If you have been following my running spreadsheet of upcoming medical conference deadlines, you know that ASCO is almost upon us. Every year, I see the same frantic emails: clinicians, fellows, and hospital administrators trying to parse the difference between treatment modalities before stepping into the lecture halls. If you are preparing for your ASCO session prep, you need to cut through the marketing fluff. We are here to talk about clinical reality, not buzzwords.
Here’s a story that illustrates this perfectly: was shocked by the final bill.. Before we dive into the science, let’s get one thing clear: oncology is moving away from the “one-size-fits-all” approach. Whether you are reviewing materials from the latest AACR conference or looking ahead to the clinical updates at ASCO, understanding the fundamental difference between immunotherapy vs targeted therapy is the bedrock of your clinical decision-making. And, if you’re reading this, do me a favor: when you leave the conference, ask yourself, “What will I do differently on Monday?” If the session doesn’t give you a actionable answer to that, it’s just noise.
Defining the Basics: Immunotherapy vs. Targeted Therapy
The confusion often stems from the fact that both approaches represent the height of precision oncology. However, their mechanisms of action are fundamentally distinct. One acts on the enemy (the cancer cell), while the other acts on the defensive line (your immune system). Let’s break it down before you get lost in a sea of posters and abstract decks.
Targeted Therapy: Precision at the Molecular Level
Targeted therapy is about interference. These treatments are drugs—usually small molecules or monoclonal antibodies—designed to interfere with specific proteins or genes that contribute to cancer cell growth and survival. Think of it as putting a lock on the “go” button of a cancer cell’s signaling pathway.
Immunotherapy: Empowering the Host Response
Immunotherapy doesn’t necessarily target the cancer cell directly. Instead, it targets the immune system’s ability to “see” the cancer. Exactly.. It releases the brakes (like in the case of checkpoint inhibitors) or trains the immune system to recognize tumor antigens. It’s an indirect strategy that relies on the host’s biology to do the heavy lifting.
Precision Oncology and the Role of Biomarkers
If you are attending ASCO sessions on precision oncology, you will hear a lot about biomarkers. Please, look past the hype. I have spent 11 years watching people get excited over a single abstract that claims a “breakthrough,” only to see the data fall apart in Phase III trials or fail to gain traction in NCCN guidelines.
Ask yourself this: biomarkers are the gatekeepers. Before selecting between these oncology treatment types, you must have a clear understanding of the NCCN clinical practice guidelines. Targeted therapy requires a biopsy that yields enough molecular data to identify a specific driver mutation. If the biopsy is insufficient, the therapy is irrelevant. Conversely, immunotherapy often relies on markers like microsatellite instability (MSI-H) or tumor mutational burden (TMB). Don’t just order the test; understand why you are ordering it and how the result changes your treatment path on that following Monday.
Clinical Trials and the “Single Abstract” Trap
As a conference editor, one of my biggest pet peeves is overclaiming outcomes from a single abstract. We see it every year: a Phase I study shows an impressive response rate in a tiny cohort, and suddenly it’s hailed as the “next standard of care.” Take a deep breath. Translational research is a marathon, not a sprint.
When you attend your ASCO sessions, look for:
The Rise of AI and Computational Oncology
We are entering an era of AI-driven drug discovery and treatment selection. There is a lot of buzz surrounding “computational oncology,” but most of it is just marketing fluff designed to sell software platforms. Real utility lies in the integration of multi-omic data—genomics, proteomics, and imaging—to better predict which patient will respond to immunotherapy vs targeted therapy.
When you attend sessions regarding AI at ASCO, ask the presenters: “How does this model integrate with existing clinical workflows?” If they don’t have an answer, mark it down as a secondary concern. Your workflow is already complex enough without adding “black box” tools that don’t provide actionable clinical insights.
Preparing for ASCO: A Checklist for the Clinician
I keep a rigid schedule for these conferences. You should too. Before you land, ensure you have a plan for the sessions you attend.
- Review the NCCN Updates: If a session promises a new treatment approach, check if it aligns with or contradicts existing NCCN guidelines. If it contradicts them, look for the data that justifies the deviation.
- Identify Your Attendance Goals: Why are you going to this session? Is it for clinical application, research networking, or administrative planning?
- Target the Right Audience: Does the agenda description specify who should attend? If it’s too vague, it’s usually a red flag that the content will be too broad or too promotional.
Sharing Your Insights
Knowledge is only useful if it’s shared. After you attend these sessions, make sure to disseminate the findings within your oncology team. You can share this resource with your colleagues here:
Share on Facebook | Share on X (Twitter)
Final Thoughts: The Monday Morning Test
The world of oncology is fast-paced, but don’t melanoma research congress 2026 agenda let the speed blind you to the substance. Whether you are dealing with targeted agents or immune checkpoint inhibitors, the goal remains the same: improving patient outcomes through evidence-based practice.
As you navigate the conference halls this year, ignore the buzzwords. Look for the limitations in the abstracts, verify the methodology of the clinical trials, and always bring your questions back to the bedside. Most importantly, keep that running spreadsheet of what you learn, and keep asking yourself: “What will I do differently on Monday morning to improve the care I provide?” If you can’t answer that, then you’re not attending an educational session—you’re just attending a trade show.
